Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.

Erwan Muros-Le RouzicYanic HeerSean YiuViola TozziStefan BraunePhilip van HövellArnfin BergmannCorrado BernasconiFabian ModelLicinio Craveironull null

Published in: Journal of central nervous system disease (2024)

OPERA I (NCT01247324), OPERA II (NCT01412333).

Keyphrases

multiple sclerosis
white matter
case control
skeletal muscle